DE60028996D1 - Behandlung von krebs durch erhöhung des malonyl-coa-spiegels - Google Patents

Behandlung von krebs durch erhöhung des malonyl-coa-spiegels

Info

Publication number
DE60028996D1
DE60028996D1 DE60028996T DE60028996T DE60028996D1 DE 60028996 D1 DE60028996 D1 DE 60028996D1 DE 60028996 T DE60028996 T DE 60028996T DE 60028996 T DE60028996 T DE 60028996T DE 60028996 D1 DE60028996 D1 DE 60028996D1
Authority
DE
Germany
Prior art keywords
fatty acid
inhibition
cpt
fas
malonyl coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60028996T
Other languages
English (en)
Other versions
DE60028996T2 (de
Inventor
S Pizer
A Townsend
P Kuhajda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School of Medicine of Johns Hopkins University
Original Assignee
Johns Hopkins University
School of Medicine of Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University, School of Medicine of Johns Hopkins University filed Critical Johns Hopkins University
Publication of DE60028996D1 publication Critical patent/DE60028996D1/de
Application granted granted Critical
Publication of DE60028996T2 publication Critical patent/DE60028996T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60028996T 1999-11-12 2000-11-13 Behandlung von krebs durch erhöhung des malonyl-coa-spiegels Expired - Fee Related DE60028996T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16476599P 1999-11-12 1999-11-12
US16476899P 1999-11-12 1999-11-12
US164765P 1999-11-12
US164768P 1999-11-12
PCT/US2000/031067 WO2001034145A1 (en) 1999-11-12 2000-11-13 Treating cancer by increasing intracellular malonyl coa levels

Publications (2)

Publication Number Publication Date
DE60028996D1 true DE60028996D1 (de) 2006-08-03
DE60028996T2 DE60028996T2 (de) 2007-02-08

Family

ID=26860829

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60028996T Expired - Fee Related DE60028996T2 (de) 1999-11-12 2000-11-13 Behandlung von krebs durch erhöhung des malonyl-coa-spiegels

Country Status (12)

Country Link
US (1) US20020187534A1 (de)
EP (1) EP1227810B8 (de)
JP (1) JP2003513920A (de)
KR (4) KR20070106648A (de)
AT (1) ATE330598T1 (de)
AU (3) AU784495B2 (de)
CA (1) CA2391277A1 (de)
DE (1) DE60028996T2 (de)
DK (1) DK1227810T3 (de)
ES (1) ES2267587T3 (de)
PT (1) PT1227810E (de)
WO (1) WO2001034145A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354196B1 (de) * 2000-11-27 2010-09-15 Minerva Biotechnologies Corporation Diagnostika, drogenscreening und behandlung für krebs
WO2003037323A2 (en) * 2001-10-26 2003-05-08 MEDIGENE AG Gesellschaft für Molekularbiologische Kardiologie und Onkologie Inhibitors of the fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction
WO2003066043A1 (en) * 2002-02-08 2003-08-14 John Hopkins University School Of Medicine Stimulation of cpt-1 as a means to reduce weight
BRPI0312413A2 (pt) * 2002-07-01 2016-08-02 Fasgen Llc compostos, composições farmacêuticas contendo os mesmos, e método de utilização para os mesmos
US20070142456A1 (en) * 2002-10-31 2007-06-21 Fasgen, Llc Method for inhibiting cancer development by fatty acid synthase inhibitors
EP1594439A2 (de) 2003-02-13 2005-11-16 Albert Einstein College Of Medicine Of Yeshiva University Regulierung der nahrungsaufnahme und glukoseproduktion durch modulation der spiegel von langkettigem fettsäureacyl-coa im hypothalamus
US8071645B2 (en) 2003-06-12 2011-12-06 The Regents Of The University Of Colorado Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
US7510710B2 (en) 2004-01-08 2009-03-31 The Regents Of The University Of Colorado Compositions of UCP inhibitors, Fas antibody, a fatty acid metabolism inhibitor and/or a glucose metabolism inhibitor
ITMI20040230A1 (it) * 2004-02-12 2004-05-12 Defiante Farmaceutica Lda Composti ad attivita' antitumorale
AU2006239896A1 (en) * 2005-04-28 2006-11-02 The Regents Of The University Of Colorado Therapeutic bifunctional compounds
EP1877047A2 (de) 2005-05-02 2008-01-16 The Regents of the University of Colorado Systeme und verfahren zur behandlung menschlicher entzündungskrankheiten und proliferativer erkrankungen mit einer kombination von verbindungen oder einer für die hemmung des fettsäurestoffwechsels und der glykolyse sorgenden bifunktionellen verbindung
WO2007117038A1 (ja) * 2006-04-07 2007-10-18 Japanese Foundation For Cancer Research 癌の予防・治療剤
WO2008106796A1 (en) * 2007-03-08 2008-09-12 University Health Network Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity
WO2008109991A1 (en) 2007-03-09 2008-09-18 University Health Network Inhibitors of carnitine palmitoyltransferase and treating cancer
EP3048168A1 (de) * 2007-07-27 2016-07-27 Vesta Therapeutics, Inc. Verfahren zur reduzierung intrazellulärer fette aus säugerzellen
US8680282B2 (en) * 2007-08-01 2014-03-25 University Health Network Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer
US8394377B2 (en) 2008-02-21 2013-03-12 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
WO2010008554A2 (en) 2008-07-14 2010-01-21 The Regents Of The University Of Colorado Methods and products for treating proliferative diseases
JP5317919B2 (ja) * 2009-10-05 2013-10-16 花王株式会社 Ｇｉｐ上昇抑制剤の評価又は選択方法
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
US20190300857A1 (en) * 2016-10-17 2019-10-03 Keio University Undifferentiated stem cell-removing agent, and method for removing undifferentiated stem cells
US20220244245A1 (en) * 2019-04-15 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) A method of profiling the energetic metabolism of a population of cells
CN113604573A (zh) * 2021-09-14 2021-11-05 北京大学第三医院（北京大学第三临床医学院） 一种使用至少八种脂肪酸代谢关键酶基因检测方法以及试剂盒
CN113549702A (zh) * 2021-09-14 2021-10-26 北京大学第三医院（北京大学第三临床医学院） 一种人脂肪酸代谢关键酶基因检测方法以及试剂盒

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
MX9304501A (es) * 1992-07-24 1994-04-29 Univ Johns Hopkins Quimioterapia para cancer.
US5539132A (en) * 1994-01-24 1996-07-23 Johns Hopkins University Cerulenin compounds for fatty acid synthesis inhibition
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Also Published As

Publication number Publication date
EP1227810B1 (de) 2006-06-21
EP1227810A1 (de) 2002-08-07
AU2009227836A1 (en) 2009-11-05
DK1227810T3 (da) 2006-10-23
DE60028996T2 (de) 2007-02-08
KR20070106648A (ko) 2007-11-02
EP1227810B8 (de) 2006-08-16
US20020187534A1 (en) 2002-12-12
KR20090031957A (ko) 2009-03-30
AU784495B2 (en) 2006-04-13
ATE330598T1 (de) 2006-07-15
KR20090130151A (ko) 2009-12-17
WO2001034145A1 (en) 2001-05-17
ES2267587T3 (es) 2007-03-16
CA2391277A1 (en) 2001-05-17
PT1227810E (pt) 2006-11-30
JP2003513920A (ja) 2003-04-15
AU2006203005A1 (en) 2006-08-10
KR20020060736A (ko) 2002-07-18
AU1600701A (en) 2001-06-06

Similar Documents

Publication Publication Date Title
DE60028996D1 (de) Behandlung von krebs durch erhöhung des malonyl-coa-spiegels
Gao et al. Stress granule: a promising target for cancer treatment
Vriend et al. The Keap1-Nrf2-antioxidant response element pathway: a review of its regulation by melatonin and the proteasome
Namdar et al. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents
Kolbe et al. 4‐n‐butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation
Abboud et al. Antitumor action of amygdalin on human breast cancer cells by selective sensitization to oxidative stress
Baek et al. Sesamol decreases melanin biosynthesis in melanocyte cells and zebrafish: Possible involvement of MITF via the intracellular cAMP and p38/JNK signalling pathways
Yang et al. What has passed is prolog: new cellular and physiological roles of G6PD
Gogebakan et al. Role of propolis on tyrosine hydroxylase activity and blood pressure in nitric oxide synthase-inhibited hypertensive rats
Yeh et al. Terminalia catappa Exerts Antimetastatic Effects on Hepatocellular Carcinoma through Transcriptional Inhibition of Matrix Metalloproteinase‐9 by Modulating NF‐κB and AP‐1 Activity
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
MA27609A1 (fr) Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
ATE509014T1 (de) Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
NO20033665D0 (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
ATE487475T1 (de) Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer
ATE341539T1 (de) Malonyl coa-decarboxylase inhibitoren als stoffwechselmodulatoren
ATE375810T1 (de) Cyanoamid-verbindungen als nützliche malonyl-coa decarboxylase-hemmer
Chen et al. Antiphotoaging effect of boiled abalone residual peptide ATPGDEG on UVB-induced keratinocyte HaCaT cells
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
Velmurugan et al. Excavatolide B inhibits nonsmall cell lung cancer proliferation by altering peroxisome proliferator activated receptor gamma expression and PTEN/AKT/NF‐Kβ expression
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
ATE269700T1 (de) Verwendung von docetaxel für die behandlung von hepatozelluläre krebs
Al-Majed Probucol attenuates oxidative stress, energy starvation, and nitric acid production following transient forebrain ischemia in the rat hippocampus
BRPI0416994A (pt) inibidores de proteìna cinase com base em indolinona avançada
DE60140964D1 (en) Sphingolipiden

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE, B

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee